Gilead Sciences

New Data Shows Promise Involving Lenacapavir for the Treatment of HIV
New Data Shows Promise Involving Lenacapavir for the Treatment of HIV
BioSpace
Gilead Sciences
lenacapavir
HIV
Flag link:
Experimental HIV drug seems effective at a twice-a-year dose, study finds
Experimental HIV drug seems effective at a twice-a-year dose, study finds
Stat
HIV
Gilead Sciences
lenacapavir
clinical trials
Flag link:
Go or no go? Pandemic looms over FDA timelines
Go or no go? Pandemic looms over FDA timelines
EP Vantage
Jazz Pharma
Gilead Sciences
Galapagos
GSK
FDA
pandemic
COVID-19
Flag link:
After its $2B Gilead pact, Goldfinch Bio nabs a cool $100M series B
After its $2B Gilead pact, Goldfinch Bio nabs a cool $100M series B
Fierce Biotech
Goldfinch Bio
Gilead Sciences
Kidney Genome Atlas
funding
Flag link:
Gilead's long-awaited remdesivir price is $3,120, in line with watchdog estimates
Gilead's long-awaited remdesivir price is $3,120, in line with watchdog estimates
Fierce Pharma
drug pricing
Gilead Sciences
COVID-19
remdesivir
Flag link:
Price for Gilead's COVID-19 drug should shrink if cheap steroid widely used, ICER says
Price for Gilead's COVID-19 drug should shrink if cheap steroid widely used, ICER says
BioPharma Dive
Gilead Sciences
remdesivir
ICER
drug pricing
steriod
Flag link:
Gilead pens $1.5B buyout option deal for Pionyr
Gilead pens $1.5B buyout option deal for Pionyr
Fierce Biotech
Gilead Sciences
Pionyr
M&A
immuno-oncology
Flag link:
Gilead to Test Inhaled Form of Remdesivir in COVID-19 Starting in August
Gilead to Test Inhaled Form of Remdesivir in COVID-19 Starting in August
BioSpace
Gilead Sciences
remdesivir
inhaled drugs
COVID-19
pandemic
clinical trials
Flag link:
Does Gilead Have a Cure for the Coronavirus?
Does Gilead Have a Cure for the Coronavirus?
Motley Fool
Gilead Sciences
remdesivir
COVID-19
Flag link:
Gilead will test remdesivir in children with COVID-19
Gilead will test remdesivir in children with COVID-19
Pharmaforum
Gilead Sciences
remdesivir
pediatric
clinical trials
COVID-19
Flag link:
Gilead sees better days ahead for CAR-T therapy Yescarta with Amsterdam manufacturing hub online
Gilead sees better days ahead for CAR-T therapy Yescarta with Amsterdam manufacturing hub online
Fierce Pharma
Gilead Sciences
CAR-T
Yescarta
Amsterdam
drug manufacturing
Flag link:
Could Gilead Sciences Have an HIV Cure Waiting in the Wings?
Could Gilead Sciences Have an HIV Cure Waiting in the Wings?
Motley Fool
Gilead Sciences
HIV
bNab
Flag link:
AstraZeneca's Acquisition of Gilead Would Create a COVID-19 Colossus -- but Don't Bet on Seeing It Happen
AstraZeneca's Acquisition of Gilead Would Create a COVID-19 Colossus -- but Don't Bet on Seeing It Happen
Motley Fool
AstraZeneca
Gilead Sciences
M&A
COVID-19
Flag link:
Gilead files remdesivir for EU approval, with a verdict possible “in weeks”
Gilead files remdesivir for EU approval, with a verdict possible “in weeks”
Pharmaforum
EMA
Europe
Gilead Sciences
remdesivir
COVID-19
Flag link:
Gilead builds case for filgotinib in active psoriatic arthritis
Gilead builds case for filgotinib in active psoriatic arthritis
Fierce Biotech
Gilead Sciences
Galapagos
filgotinib
clinical trials
psoriatic arthritis
Flag link:
AstraZeneca reportedly eyed a merger with Gilead. But does 'Gileaz' make sense?
AstraZeneca reportedly eyed a merger with Gilead. But does 'Gileaz' make sense?
Fierce Pharma
M&A
Gilead Sciences
AstraZeneca
Flag link:
AstraZeneca Approaches Gilead About Potential Merger
AstraZeneca Approaches Gilead About Potential Merger
Bloomberg
AstraZeneca
Gilead Sciences
M&A
Flag link:
Could Gilead's COVID-19 Drug Make $7 Billion Per Year?
Could Gilead's COVID-19 Drug Make $7 Billion Per Year?
Motley Fool
Gilead Sciences
COVID-19
remdesivir
Flag link:
Gilead shows durability of filgotinib ahead of face-off with AbbVie
Gilead shows durability of filgotinib ahead of face-off with AbbVie
Fierce Biotech
Gilead Sciences
Galapagos
clinical trials
filgotinib
rheumatoid arthritis
Flag link:
Gilead's next step on coronavirus: inhaled remdesivir, other easier-to-use versions
Gilead's next step on coronavirus: inhaled remdesivir, other easier-to-use versions
Reuters
Gilead Sciences
drug development
remdesivir
COVID-19
Flag link:

Pages